A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This open label study will evaluate the safety and efficacy of riluzole in patients with
PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient,
with a one month follow up at week 16.